About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering
from serious illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its
biologics manufacturing expertise to strive for solutions that improve health
outcomes and dramatically improve people’s lives. A biotechnology pioneer
since 1980, Amgen has grown to be the world’s largest independent
biotechnology company, has reached millions of patients around the world
and is developing a pipeline of medicines with breakaway potential.
Pioneering Medicines Amgen’s medicines treat serious illnesses. We have a presence in more than 50 countries
worldwide and have reached millions of people in the fight against cancer, kidney disease,
rheumatoid arthritis, bone disease and other serious illnesses. Our medicines typically address
diseases for which the number of effective treatment options is limited, or they are medicines
that provide a viable option to what is otherwise available.
Innovative Research Understanding the fundamental biological mechanisms of human life is a defining feature of
Amgen’s discovery research efforts—and a major contributor to the development of Amgen’s
deep and broad pipeline of potential new medicines. Amgen’s “biology first” approach permits its
scientists to first explore the complex molecular pathways of disease before determining what
type of medicine, or modality, is most likely to deliver optimal efficacy and safety. As advances
in human genetics continue to shed new light on the molecular roots of disease, Amgen
subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator,
greatly improving how we identify and validate human disease targets.
World‐Class Manufacturing The treatment of millions of seriously ill patients worldwide depends on the safe and reliable
production of biologic medicines, which are administered by injection or intravenously. A
worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably
delivering high-quality medicines to patients who need them. Significant skill, experience,
vigilance and commitment are critical to help ensure the quality of a biologic medicine each time
a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for
patients are every bit as important as scientific innovatio